With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding cancer screening, prevention and treatment. Presenters will include Clinicians, Academics and members of the Pharmaceutical industry and we encourage presentations from the wide spectrum of cancer research, development and healthcare professionals.

This event has [CPD accreditation](http://example.com)

[www.cancersummit2015.com](http://www.cancersummit2015.com)

Hashtag: #cancer2015
Contents

Agenda ............................................................................................................................................ 5

Day 1: Diagnosis, Staging and Assessment .................................................................................... 5

Introduction by the Chair ................................................................................................................ 5

Cell-mediated anti-cancer immunotherapy; targeting chemotherapy-resistant malignant cells with personalized immunotherapy mediated by autologous and allogeneic cells ......................................................... 5

Oral Presentation ............................................................................................................................ 5

Session Break .................................................................................................................................. 5

Speakers’ photo, Refreshments, Poster viewing, Sponsors exhibition ............................................. 5

Prognostic value of repeat testing in population screening for CRC - for optimizing efficacy .......... 5

Oral Presentation ............................................................................................................................ 5

GENOMIC ANALYSIS AND BETA-PAPILLOMAVIRUS INFECTION IN CUTANEOUS SQUAMOUS CELL CARCINOMA DURING ADVANCED MELANOMA BRAF-INHIBITION THERAPY ................................................................. 5

ErbB-targeted CAR T-cell immunotherapy of cancer: a strategy to maximize the window of therapeutic opportunity .................................................................................................................... 5

Overcoming Mechanisms of Therapeutic Resistance in Advanced Castration Resistant Prostate Cancer ............................................................................................................................................. 5

Knowledgeable methods to assess and support older people with cancer; comprehensive care for older people with cancer (COCOC) ...................................................................................... 5

Oral Presentation ............................................................................................................................ 5

Session Break .................................................................................................................................. 5

Cancer Causation and Risk Communication: The gap between cancer knowledge and community perceptions ............................................................................................................................ 5

Low-dose aspirin in the prevention and the treatment of cancer: a review of observational and randomised evidence .............................................................. 5

Day 2 Session 1: Treatment ............................................................................................................ 6

Introduction by the Chair ................................................................................................................ 6

Oral presentations ............................................................................................................................ 6

1st line chemotherapy in treatment of mCRC: FOLFIRI vs FOLFIRI+bevacizumab - single institution experience ................................................................................................................................. 6

Second line treatments in advanced non-small cell lung cancer .................................................... 6

Oral Presentations ............................................................................................................................ 6

Day 2 Session 1: Quality of life ....................................................................................................... 6

Oral presentations ............................................................................................................................ 6

Oral presentations ............................................................................................................................ 6

Day 3: Therapeutics ....................................................................................................................... 7

Introduction by the Chairs .............................................................................................................. 7

From cancer genotype to phenotype by proteomics ....................................................................... 7

Vitamin D binding protein-based immunotherapy leads to reversal of the neoplastic phenotype and suppression of oncogene expression ......................................................................................... 7

Oral Presentations ............................................................................................................................ 7

Use of ESAs in treating cancer/chemotherapy-induced anemia, plus or minus IV iron .................. 7

Oral Presentations ............................................................................................................................ 7

Discussion Session .......................................................................................................................... 7

Oral Presentation ............................................................................................................................ 7

Latest developments in non-melanoma skin cancer ....................................................................... 7
Frequently asked questions about our events

- All the chicken in our lunch buffet is Halal.
- We have a number of dishes that are gluten free.
- We have a range of vegetarian dishes which are separated from the meat and fish dishes.

Discussion Sessions

Session breaks

Lunch

- All the chicken in our lunch buffet is Halal.
- We have a number of dishes that are gluten free.
- We have a range of vegetarian dishes which are separated from the meat and fish dishes.

Frequently asked questions about our events

Is the delegate list available?

Can I have the speakers slides?

Can I have a notepad?

How can I keep up to date with Euroscicon Events?

I don't want my photograph on any Euroscicon promotional material.

Is there WIFI?

Can I have a CPD certificate?
<table>
<thead>
<tr>
<th>Day 1: Diagnosis, Staging and Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>09:00 – 09:45</strong></td>
</tr>
</tbody>
</table>
| **09:45 – 10:20** | **Oral Presentation**  
*Introduction by the Chair*  
Cell-mediated anti-cancer immunotherapy; targeting chemotherapy-resistant malignant cells with personalized immunotherapy mediated by autologous and allogeneic cells  
**Registration and Refreshments**  
Professor Shimon Slavin, The International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Weizman Center, Tel Aviv, Israel |
| **10:20 – 10:40** | **Current status of minimally invasive diagnosis and staging of lung malignancies**  
Dr Jorge Pascual, MD, Assistant Professor, Mayo Clinic  
College of Medicine, Mayo Clinic, Florida, USA |
| **10:40 – 11:00** | **Oral Presentation**  
*10:40 – 10:50* NANO-FORMULATION OF NOVEL OLEIC ACID CONJUGATE SUPPRESS MOUSE SKIN TUMORS BY REGULATING P53 WT/MUT EXPRESSION  
Azmat Ali Khan³, Amer M. Alanazi¹, Mumtaz Jabeen³  
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, KSA |
| **11:20 – 11:50** | **Session Break** |
| **11:50 – 12:10** | **Prognostic value of repeat testing in population screening for CRC - for optimizing efficacy**  
Dr Pavel Elaksova MD PhD, State Research Institute, Innovative Medicine Center, Vilnius, Lithuania |
| **12:10 – 12:20** | **GENOMIC ANALYSIS AND BETA-PAPILLOMAVIRUS INFECTION IN CUTANEOUS SQUAMOUS CELL CARCINOMA DURING ADVANCED MELANOMA BRAF-INHIBITION THERAPY**  
DN Cohen, SK Lawson, AC Shaver, I DU, HP Nguyen, Q He, DB Johnson, WA Lumbang, BR Moody, JL Prescott, PK Chandra, AS Boyd, JP Zwerner, JB Robbins, SK Tyring, PL Rady, JD Chappell, Y Shyr, JA Sosman, JR Intervé, Daniel N. Cohen, MD, PhD; Department of Dermatology, Division of Dermatology and Immunodermatology, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55904, U.S.A. |
| **12:20 – 12:40** | **ErbB-targeted CAR T-cell immunotherapy of cancer: a strategy to maximize the window of therapeutic opportunity.**  
Dr John Maher, Senior Lecturer in Immunology, NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, Research Oncology, Division of Cancer Studies, Guy’s Hospital campus, St Thomas St, London, United Kingdom |
| **12:40 – 13:00** | **Overcoming Mechanisms of Therapeutic Resistance in Advanced Castration Resistant Prostate Cancer**  
Dr Natasha Kyriannis, James P. Hardymon Chair in Urology Research, Professor of Urology, Molecular Biochemistry, Pathology and Toxicology, Combs, Rm 306, University of Kentucky College of Medicine, Lexington, KY, US |
| **13:00 – 14:00** | **Session Break** |
| **14:00 – 14:20** | **Knowledgeable methods to assess and support older people with cancer; comprehensive care for older people with cancer (COCCC)**  
Dr Shane O’Hanlon, Royal Berkshire NHS Foundation Trust University of Reading, UK |
| **14:20 – 14:50** | **Oral Presentation**  
**14:20 – 14:30** SEXUAL FUNCTION OF MEN ON A PHASE III RANDOMIZED STUDY OF HIGH VERSUS STANDARD DOSE 3D-CRT/IMRT IN PATIENTS TREATED FOR LOCALIZED PROSTATE CANCER  
DW Bruner¹, S Deshmukh, J Michalski, J Purdy, W Bosch, JP Bahary, M Patel, M Parliament, M Lock, HY Lau, D Hamstra, MSuntharalingam, S Fisher, L Soubami, E Vigneault, M Seider, H Gay, S Rosenthal, H Sandler, B Movsas, MD; Deborah Watkins Bruner, PhD, FAAN, Robert W. Woodruff Professor of Nursing Nell Hodgson Woodruff School of Nursing, Professor of Radiation Oncology, Associate Director for Outcomes Research, Winship Cancer Institute, Emory University, 1520 Clifton Road, Room 232, Atlanta GA 30322-4201 |
| **14:30 – 14:40** | **LAYING THE FOUNDATION FOR A DICYCLOPLATIN CLINICAL TRIAL FOR CANCER CHEMOTHERAPY IN THE UNITED STATES**  
Ye Li², Yang XQ², Song QH², Mueller MD², Remick SC¹  
¹ Department of Biochemistry, School of Medicine, Department of Basic Pharmaceutical Sciences, School of Pharmacy, and Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia, USA.  
² Beijing Sopo-Xingfa Pharmaceutical, Inc, Beijing, China. |
| **14:40 – 14:50** | **CAUSES OF UNEQUAL OUTCOMES IN WOMEN WITH BREAST CANCER**  
R Lawrence, S Senvariratne, N Scott, I Campbell  
Corresponding Author: Professor Rod Lawson  
Assistant Dean, Waikato Clinical Campus, University of Auckland  
Peter Rothwell Academic Centre, Waikato Hospital, Private bag 3200, Hamilton, New Zealand, Postcode 3204 |
| **14:50 – 15:20** | **Session Break** |
| **15:20 – 15:40** | **Cancer Causation and Risk Communication: The gap between cancer knowledge and community perceptions**  
Dr Bernard W. Stewart PhD FRACI DipLaw, Professor, Faculty of Medicine, UNSW and Head, Cancer Control Program, South East Sydney Public Health Unit, Locked Bag 88, Randwick, Australia |
| **15:40 – 16:00** | **Low-dose aspirin in the prevention and the treatment of cancer: a review of observational and randomised evidence.**  
Professor Peter Creighton Elwood, Cardiff University, Penylan, Cardiff, United Kingdom |
| **16:00** | **Chairman’s Summing Up** |

**Agenda**  
(Talk times include 5 – 10 minutes for questions)
Day 2 Session 1: Treatment

09:00 – 09:30 Exhibitions open

09:30 – 10:00 Introduction by the Chair

The Role of Intraoperative Radiation in Retroperitoneal Sarcoma

Dr Richard Gray, Consultant, Section of Surgical Oncology, Mayo Clinic, US

10:00 – 10:20 EWS and GWAS go together in cancer control

Dr Mukeesh Verma, Ph.D, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA

10:20 – 10:40 Breast Cancer, Chemoresistance and ErbB receptors

Professor Zhujiang Wang, PhD, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada

10:40 – 11:10 Oral presentations

10:40 – 10:50 DETECTION OF ANTICANCER RESPONSE BY MOLECULAR IMAGING TECHNIQUES

S. M. PHYU, C. TSENG, T.A.D. SMITH
Biomedical Physics building, Forsterhill, University of Aberdeen, AB25 ZD

10:50 – 11:00 IDENTIFICATION OF POTENTIAL BINDING PARTNERS FOR THE N-TERMINOAL DOMAIN OF OCLCLUDIN

T. Benci, M. Lloyd2, and R. Mcraey1
Pharmacy and Pharmacology, University of Bath, Claverton down, Bath, BA2 7AY, United Kingdom

11:00 – 11:10 BODY SURFACE AREA-BASED VERSUS CONCENTRATION-BASED DOSIMETRY OF INTRAPERITONEAL CHEMOTHERAPY IN PERITONEAL CARCINOMATOSIS TREATMENT

J. Lemoine, M. Sc, K. Van der Speeten, MD, PhD
Department of Surgical Oncology, Zielenhuis Oost-Limburg, Schiepse Box 6, Genk 3600, Belgium

11:10 – 11:40 Session Break

11:40 – 12:00 1st line chemotherapy in treatment of mCRC: FOLFOX vs FOLFIRI+bevacizumab - single institution experience

Dr Zoran Rakovic, MD, PhD, Head of Clinical Ward, Department of Oncology, University of Zagreb, Croatia

12:00 – 12:20 Second line treatments in advanced non-small cell lung cancer

Dr. Mircea Dediu MDPhD, Medical Oncology senior consultant, Chief of Medical Oncology Department, Institute of Oncology* Alexandru Treistoreanu* Bucharest, Bucharest, Romania

12:20 – 12:40 Experience of the European Institute of Oncology in the use of intra-operative radiotherapy with electrons (ELIOT)

Dr Simonetta Monti, Senior Assistant, Medico Assistente, Senologia Division, Reparto di Senologia, Milano, Italy

12:40 – 13:10 Oral Presentations

12:40 – 12:50 EPAGLLOCATECHIN-3-GALLATE INHIBITS NICOTINE-INDUCED MIGRATION AND INVASION VIA SUPPRESSION OF ANGIogenesis AND EPITHELIAL-MESenchymal TRANSITION IN NON-SMALL CELL LUNG CANCER CELLS

Jingi Shi, Pei Liu, Wenzhang Zhang, Xin Liu, Bihua Lin and Xudong Tang*1
*Correspondence to: Dr. Xudong Tang, Institute of Biochemistry and Molecular Biology, Guangdong Medical College, 2 Wenming Donglu, Xishan, Zhanjiang, Guangdong 524023, P.R. China

12:50 – 13:00 HUMAN PAPILLOVIRUSES MAY NOT PLAY A ROLE IN THE DEVELOPMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA AMONG FILIPINOS

PM Albang1,2, D Holzinger3, C Lumang-Salvador4, J Orosa III5, S Racelis6, M Leaoa, D Sanchez Jr6, LM Angeles7, G Halec8, M Schmitt9, JD Ramos2, and M Pawli2
1University of Santo Tomas, Manila, Philippines; 2Division of Genome Modifications and Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany; and 3Mariano Marcos Memorial Hospital and Medical Center, Ilocos Norte, Philippines

13:00 – 13:10 PROTEOMIC INSTABILITY OF CANCER: THE HSF1-MEDIATED PROTEOTOXIC STRESS RESPONSE CRITICALLY REPRESSES TUMOR-SUPPRESSIVE ANTIPLIOIDGENESIS

Z Tang, S Dai, Y He, RA Doty, LD. Shultz, SB Sampson, and C Dai
The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA

13:10 – 14:10 Session Break

Lunch, Poster viewing, Sponsors exhibition

14:10 – 14:40 Introduction by the chair

Nutritional supplement in patients with cancer

Professor Robert Thomas, Bedford and Addenbrooke’s Cambridge University, Hospitals, UK

14:40 – 15:10 Oral Presentations

14:40 – 14:50 MEASURING THE PREVALENCE, SEVERITY AND QUALITY OF LIFE PREDICTORS OF CONCURRENT SYMPTOMS IN CANCER PATIENTS IN JORDAN

M. Al Qadire, M. Al Khalalah
Al-Bayt University, Mafrq 25113, Jordan

14:50 – 15:00 IMMUNE ACTIVATION BY ONCOTHERMIA

O. Szasz, A. Szasz
St. Istvan University, Biotechnics Department, address: Paty, Ibolya u. 2., 2071, Hungary

15:00 – 15:10 BREAKING TUMOUR TOLERANCE BY SUCCESSFULLY SYNONCROMISING ANTI-TUMOUR IMMUNE RESPONSES WITH TIMED DELIVERY OF THERAPIES

Bj Coventry* and ML Ashdown1
1Surgery and Immunology, University of Adelaide, LS EHB, Royal Adelaide Hospital, North Tce Adelaide SA 5000; 1Medicine, University of Melbourne, Melbourne, VIC, Australia

15:10 – 15:30 Measuring Quality of Survival and Impact of Adverse Events on Quality of Life in Metastatic Disease

Dr Stacie Hudgens, Strategic Lead, Quantitative Science and Managing Partner, Clinical Outcomes Solutions, Tucson, Arizona, USA

15:30 – 16:00 Session Break

Refreshments, Last poster viewing, Last Sponsors exhibition

16:00 – 16:30 Oral Presentations

16:00 – 16:10 XRC11 GENE POLYMORPHISMS AND susceptibility to LUNG ADENOCARCINOMA IN SERBIA

Department of Experimental Oncology, Laboratory for Molecular Genetics, Institute for Oncology and Radiology of Serbia, Pasteurova 14, 11000 Belgrade, Serbia

16:10 – 16:20 TARGETING MMP-9 INHIBITS VASCULAR INVASION IN HEPATOCELLULAR CARCINOMA

Mohammed A.F. Elwey, Mohammed M. Al-Gayyar, Mona F. Schaalan, Khaled H. Abd El Galil, Mohamed A.Ebrahim, Madhoub M. El-Shishawy, B Mohamed Mahmoud

16:20 – 16:30 CERVICAL CANCER SCREENING WITH CLINIC-BASED PAP TEST VERSUS HOME HPV TEST AMONG SOMALI IMMIGRANT WOMEN IN MINNESOTA: A PILOT RANDOMIZED CONTROLLED TRIAL

KS Okuyemi, B Sewali, A Askhir, J Belinson, R. Vogel, A Joseph, RG Ghebre
Presenting author contact information: 717 Delaware Street, SE, Minneapolis, Minnesota, 55414, USA

16:30 – 16:50 Targeted alpha therapy for cancer & the use of radioisotopes

Dr Graeme Melville, Macquarie University, Sydney, Australia

16:50 – 17:00 Chairman’s Summing Up

Close of Session
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:45</td>
<td>Exhibitions open</td>
<td>Dr. Sophia Karagiannis, King's College London School of Medicine, Guy's Tower, Guy's Hospital, London and Dr. Ann White</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Introduction by the Chairs</td>
<td>Antibody and Vaccine Group, Southampton University Hospital, UK</td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>From cancer genotype to phenotype by proteomics</td>
<td>Associate Professor Jane Lehto, Karolinska Institutet, SciLifeLab, Stockholm, Sweden</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Involvement of key components of Wnt signalling in human astrocytic brain tumours</td>
<td>Professor Dr. sc. Nives Pećina-Slaus, Department of Biology, Laboratory for Neurooncology, Croatian Institute for Brain Research, Medical School University of Zagreb, Zagreb, Croatia</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Session Break</td>
<td>Speakers' photo, Refreshment, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>11:30–12:15</td>
<td>Vitamin D binding protein-based immunotherapy leads to reversal of the neoplastic phenotype and suppression of oncogene expression</td>
<td>Dr. Heinz Reinwald, Dr. Reinwald Academy, Italy</td>
</tr>
<tr>
<td>12:15 – 12:45</td>
<td>Oral Presentations</td>
<td>Dr. David Henry, Vice Chair, Department of Medicine, Clinical Professor of Medicine University of Pennsylvania, USA, USA</td>
</tr>
<tr>
<td>12:45 – 13:15</td>
<td>Use of ESAs in treating cancer/chemotherapy-induced anemia, plus or minus IV iron</td>
<td>Dr. Jin, Department of Internal Medicine, Neurosurgery and Surgery, Institute of Health Sciences, Gyeongsang National University School of Medicine, 90 Chilam-dong Jinju 660-702, Korea.</td>
</tr>
<tr>
<td>13:15 – 14:15</td>
<td>Session Break</td>
<td>Lunch, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>14:15 – 14:45</td>
<td>Oral Presentations</td>
<td>Dr. S. Dovat, C. Song, C. Gowda, Y. Ding, S. Muthusami, E. Dovat and K.J. Payne Department of Pediatrics, 500 University Drive, P.O. Box 850, Hershey, PA, USA</td>
</tr>
<tr>
<td>14:45 – 15:15</td>
<td>Session Break</td>
<td>Refreshments, Last poster viewing, Last Sponsors exhibition</td>
</tr>
<tr>
<td>15:15 – 16:00</td>
<td>Discussion Session</td>
<td></td>
</tr>
<tr>
<td>16:00 – 16:15</td>
<td>Oral Presentation</td>
<td>Professor Patricia Tak Hing Tai, University of Saskatchewan, Regina, Saskatchewan, Canada</td>
</tr>
<tr>
<td>16:15 – 16:45</td>
<td>Latest developments in non-melanoma skin cancer</td>
<td></td>
</tr>
<tr>
<td>16:45 – 17:00</td>
<td>Chairman's Summing Up</td>
<td>Close of Meeting</td>
</tr>
</tbody>
</table>
About the Speakers

Day 1

Shimon Slavin, The International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Weizman Center, Tel Aviv, Israel
Shimon Slavin, MD, Professor of Medicine, pioneered the use of personalized anti-cancer immunotherapy mediated by donor lymphocytes and innovative methods for stem cell transplantation for malignant and non-malignant disorders, including treatment of autoimmune diseases and induction of transplantation tolerance to bone marrow and organ allografts. More recently, Slavin pioneered the use of multi-potent mesenchymal stromal cell for regenerative medicine. Slavin authors 4 books, 660 scientific publications and serves on many editorial boards and many national and international advisory boards. Slavin received many international awards in recognition of his contributions for treatment of malignant and non-malignant disorders.

Jorge Pascual, MD, Assistant Professor, Mayo Clinic College of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Florida, USA
After graduating from medical school cum laude at the Federal University of Rio de Janeiro, Brazil, Dr. Pascual pursued a residency program in Internal Medicine at the Mayo Clinic, Rochester, MN, USA, followed by a fellowship in Pulmonary and Critical medicine at Duke University, NC, USA. Since 1997, he has been a working as a pulmonologist at the Mayo Clinic Florida, USA. Main clinical and research interests relate to minimally invasive staging of lung cancer, and interventional bronchoscopy. Dr. Pascual also serves as the Chair of the Clinical practice, coordinating inpatient, outpatient, and surgical practices, and quality improvement initiatives.

Rui Amaral Mendes, The Catholic University of Portugal and Case Western Reserve University, Cleveland, OH, USA
Prof. Rui Amaral Mendes attained his DMD degree from the University of Porto and proceeded with his studies at the VU Universiteit Amsterdam where he defended his doctoral thesis under the supervision of Prof. Isaac van der Waal.

Is currently the Director of the Post-Graduation Program on Oral and Maxillo-Facial Medicine and Pathology of the Catholic University of Portugal and was recently appointed Adjunct Professor of Oral Medicine at the Department of Oral and Maxillofacial Medicine of the Case Western Reserve University.

He worked as Assistant reviewer in the V World Workshop on Oral Medicine – “Genetics/epigenetics of oral mucosal premalignancy” and is also member of the Research Interest Group "Head & Neck Oncology" of the International Association of Oral and Maxillofacial Surgeons.

In June 2013 was designated Section Head of the Bone Complications Section of the Oral Care Study Group, Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).

He is member of the Editorial Board of the "Journal of Carcinogenesis & Mutagenesis" and Associate Editor of the "British Medical Journal – Case Reports".

Bernard W. Stewart, PhD FRACI DipLaw, Professor, Faculty of Medicine, UNSW and Head, Cancer Control Program, South East Sydney Public Health Unit, Locked Bag 88, Randwick, Australia
Bernard Stewart has an MSc from University of New South Wales (UNSW) and PhD from University of London and is currently Head, Cancer Control Program at South Eastern Sydney Public Health Unit. He has a professorial appointment in Faculty of Medicine, UNSW. His research focus is prevention of cancer attributable to environmental exposures. Professor Stewart is a Fellow of the Royal Australian Chemical Institute and in 2010 was admitted as a lawyer. For International Agency for Research on Cancer (IARC), he has been involved with the IARC Monographs on Carcinogenic Risks program and most recently co-edited World Cancer Report 2014.
Peter Creighton Elwood, Cardiff University, Penylan, Cardiff, United Kingdom
For twenty years Elwood worked with Archie Cochrane and succeeded him as Director of an MRC Research Unit. On retirement he was granted an honorary professorship in Cardiff University. Together with Cochrane, Elwood reported the first randomised trial of aspirin prophylaxis in vascular disease in 1974. He continues to have an involvement in work on aspirin prophylaxis of vascular disease and of cancer, and, most recently on aspirin and an increase in the survival of patients with cancer.

Pavel Elsakov, MD PhD, State Research Institute, Innovative Medicine Center, Vilnius, Lithuania
Pavel Elsakov (1957.05.08) M.D, PhD. Lithuania.
Specialist in Gastroenterology and Oncology.
1) Vilnius Centre Policlinic. Diagnostics Centre.
2) State Research Institute. Innovative Medicine Centre.
In 1995 year (Lithuania) obtained PhD degree.
He is a member of UICC fellows association.
Awarded of UICC found ICRETT grants 1992 (Israel), 1997 (Israel), 2003 (France).
Awarded of Nordic Baltic found grants 1994, 1998 years (Denmark).
His main areas of interest are hereditary cancer and colorectal cancer detection and prevention.
He published more than the 50 national and international research publications.

Day 2
Richard Gray, Consultant, Section of Surgical Oncology, Mayo Clinic, US
Dr. Gray is a consultant in the section of surgical oncology and an associate professor of surgery at the Mayo Clinic in Arizona. He trained in surgery at the Mayo Clinic and in surgical oncology at the H. Lee Moffitt Cancer Center. His clinical and research interests include retroperitoneal sarcoma, melanoma, and breast cancer. He has published more than 90 peer-reviewed manuscripts and serves as an associate editor and reviewer for multiple surgical and surgical oncology journals. He has received multiple awards including the Mayo Clinic Distinguished Educator for 2014.

Mukesh Verma, Ph.D., Branch Chief, Methods and Technologies Branch, Program Director. Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences. National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA
Dr. Mukesh Verma is a Program Director and Branch Chief in the Methods and Technologies Branch (MTB), Epidemiology and Genomics Research Program (EGRP) of the National Cancer Institute (NCI), National Institutes of Health (NIH). He provides direction in the areas of biomarkers, early detection, risk assessment, epidemiology and prevention of cancer. Dr. Mukesh Verma holds a M.Sc. from Pantnagar University and a Ph.D. from Banaras Hindu University. He has published 137 research articles, book chapters reviews and edited three books in cancer biomarker, epigenetics and epidemiology field. He represents NCI in the NIH Epigenome Roadmap.

Zhixiang Wang, PhD, Department of Medical Genetics, Signal Transduction Research Group, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
After obtained his PhD, Dr. Wang did his postdoctoral training at University of Toronto. He started his first independent research position as a Career Scientist at Northeastern Ontario Cancer Centre in 1996 and as an Assistant Professor at University of Ottawa in 1997. He moved to the Department of Cell Biology, University of Alberta as an Assistant Professor. He is now a Full Professor at the Department of Medical Genetics, University of Alberta. His research has focused on ErbB receptor-mediated cell signaling, receptor endocytosis, and human cancer.

Zoran Rakusic, MD, PhD, Head of Clinical Ward, Department of Oncology, University of Zagreb, Croatia

Mircea Dediu, MDPhD, Medical Oncology senior consultant, Chief of Medical Oncology Department, Institute of Oncology " Alexandru Treistareanu" Bucharest, Bucharest, Romania
Dr. Mircea Dediu is the Head of the Medical Oncology Department at the Institute of Oncology Bucharest. He served as Romanian National Representative at ESMO during 2003-2011. He was accepted as full
Janne Lehtio, Karolinska Institutet, SciLifeLab, Stockholm, Sweden
Associate Professor Janne Lehtio is principle investigator at Karolinska Institutet and head of clinical proteomics platform at Karolinska University Hospital and Science for Life Laboratory, Stockholm, Sweden. Dr Lehtio’s major research interest is to improve human proteome analysis and to use this in-depth proteome information to personalize cancer therapy. Lehtio’s group has published number of methods to improve proteome analysis in leading journals and applied these methods in biomarker and disease mechanism studies. He’s laboratory is focusing on cancer and clinical sample analysis using so called proteogenomics methods to connect information from genomics and proteomics levels.

Simonetta Monti, Senior Assistant, Medico Assistente, Senology Division, Reparto di Senologia, Milano, Italy
Degree in Medicine and Surgery (09/28/1992) vote with 110/110 degree from the Faculty of Medicine of the University ‘of L’Aquila, with a dissertation entitled “The treatment of cancer patients in the terminal phase”.
Postgraduate Diploma in General Surgery (11/11/1997) with Honours degree from the School of Specialization in General Surgery at the University ‘of L’Aquila, with a thesis entitled “Problems of surgical non-palpable lesions. A new method of preoperative localization with technetium 99m-labeled albumin.” Master’s Degree in senology (01/20/2003), from the University ‘degli Studi di Milano. From 01.07.1999 to date, serving as Senior Assistant in the Division of Breast European Institute of Oncology in Milan.

Robert Thomas, Consultant Oncologist, Cranfield University, Bedford and Addenbrooke’s Cambridge University, Hospitals, UK
A Consultant Oncologist at, Bedford and Addenbrooke’s, Hospitals. A Professor at Cranfield University and senior Clinical lecturer at Cambridge University. He treats breast, prostate and bowel cancer with chemotherapy, radiotherapy and biological therapies but is also a stronger advocate of the role of self help and lifestyle strategies to improve well-being and outcome. He is author of the book “Lifestyle and Cancer” and editor of the cancer treatment and lifestyle website cancernet.co.uk.
He has published over a hundred scientific papers and was chief investigator of the double blind randomised controlled trial of a polyphenol / antioxidant rich supplement (Pomi-T) and designed the UK’s first level 4 Cancer rehabilitation course for exercise professionals. He is a Media Spokesman and Chair of the Macmillan Cancer support exercise advisory group. In 2001 he was voted Hospital Doctor Magazine “Doctor of the Year” and in 2007 The British Oncology Association “Oncologist of the Year”.

Graeme Melville, Macquarie University, Sydney, Australia
Dr Graeme Melville was a senior nuclear researcher at St George Hospital in Sydney, Australia. In the past he was a professional tennis player, NASA astrophysics researcher (Magellan Project), university lecturer and government science policy advisor. Dr Melville has worked in a senior position with the Department of Defence and published many papers in astrophysics and nuclear physics as well as being Editor-in-Chief of an international journal. He was the recipient of the 2005 ‘Physics in Industry Day’ award and 2007 ‘Research Futures Forum’ prize. He is currently the Chairman of the Australian Institute of Physics (NSW) and has published two books. His current research involves producing Ac-225 for ‘Targeted Alpha Therapy’ (TAT) - a new kind of cancer treatment.

Day 3

Nives Pecina-Šlaus, Department of Biology, Laboratory for Neurooncology, Croatian Institute for Brain Research, Medical School University of Zagreb, Zagreb, Croatia
Nives Pecina-Slaus is full professor at the department of biology and Head of the Laboratory of neuro-oncology Croatian institute for brain research. She has received her BS in 1990, her MS in 1992, from the University of Zagreb, Faculty of Sciences, and her PhD in the field of molecular oncology in 1998, from Medical School. She was trained at Cold Spring Harbor Laboratory, New York, and at Georgetown University, Washington DC. She was granted 5 scientific projects. Her research has led to more than 100 publications – 49 scientific papers, a book, abstracts and book chapters. Her main fields of research are cancer genetics, Wnt signaling pathway, tumor suppressor genes, oncogenes, genetics of brain tumors. She is a member on editorial boards of Frontiers in Bioscience, Acta Clinica Croatica, Cancer Cell International and Croatian Medical Journal. She teaches medical biology and was mentor on numerous
theses. She was awarded three scientific awards, by Croatian Medical Association, by Academy of Medical Sciences and in 2011. She received National Science Award.

David Henry, Vice Chair, Department of Medicine, Clinical Professor of Medicine University of Pennsylvania, USA,

David H. Henry, MD is a practicing hematologist/medical oncologist and Clinical Professor of Medicine at the Pennsylvania Hospital in Philadelphia, Pennsylvania where he holds the title of Vice Chairman of the Department of Medicine. He is Editor in Chief of the Journal of Community and Supportive Oncology.

For the past 25 years, he has had a special interest in supportive oncology and participated in clinical trials using growth factors to treat cancer related anemia with or without IV iron, neutropenia, thrombocytopenia, and bone metabolism due to bone metastases.

John Maher, Senior Lecturer in Immunology, NIHR Biomedical Research Centre at Guy's and St Thomas', NHS Foundation, Trust and King's College London, Research Oncology, Division of Cancer Studies, Guy's Hospital campus, St Thomas St, London, United Kingdom

Dr John is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy for cancer and other pathologies using CAR engineered and gamma delta T-cells. He is also a consultant immunologist within King’s Health Partners and Barnet & Chase Farm NHS Trust.

Natasha Kyprianou, James F. Hardymon Chair in Urology Research, Professor of Urology, Molecular Biochemistry, Pathology and Toxicology, Combs, Rm 306, University of Kentucky College of Medicine, Lexington, KY, US

Dr. Kyprianou is currently a professor of urology, molecular and cellular biochemistry, pathology and toxicology. A leading investigator in prostate cancer research, she is internationally recognized for her seminal contributions to the identification of apoptosis as a mechanism underlying therapeutic response of breast and prostate tumors to hormone treatment. Her research focuses on apoptosis signaling during prostate cancer progression to metastasis, and development of novel molecular therapeutics targeting advanced prostate cancer. Her book entitled “Molecular Exploitation of Apoptosis Pathways in Prostate Cancer” was recently published by Imperial College Press, London, UK.

Patricia Tak Hing Tai, University of Saskatchewan, Regina, Saskatchewan, Canada

Professor Patricia Tai graduated from the University of Hong Kong in 1984 with a gold medal. She started oncologic research in University of Hong Kong. She joined the University of Saskatchewan, Canada since 1998. Her research employed the Saskatchewan Cancer Registry which is among one of the oldest registry in North America, recognized on many occasions by the North American Association with gold medals. She won many awards and was invited speaker in many conferences. She has 115 presentations, 97 abstracts and 107 full publications. She is an UpToDate author on skin cancer.

Heinz Reinwald, Dr Reinwald Academy, Italy

Doctoral degree at the faculty for philosophy and political economics in Germany. Training as alternative practitioner with particular emphasis on clinical nutrition, general regulatory medicine, immunotherapy and detoxification, practicing in own clinic in Bayreuth. Managing Director of Dr.reinwald healthcare gmbh+co kg, and dr. reinwald global health ltd. Founder and Director of Dr.Reinwald Academy for research and training in novel anticancer therapies.

Discussion Sessions

The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers session, but for discussing either general topics or specific issues.

Session breaks

All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments.

Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you.

Lunch

- All the chicken in our lunch buffet is Halal
- We have a number of dishes that are gluten free
Frequently asked questions about our events

Is the delegate list available?
Yes this is available to everyone who attends the event and our sponsors. It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event. You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever given out to third parties.

Can I have the speakers slides?
We cannot give out the slides from our speaker’s presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.

Can I have a notepad?
Notepads and pens are provided in the delegate bags and at the registration desk.

How can I keep up to date with Euroscicon Events?
To keep updated on our events and other Life Science News, please sign up for our newsletter at www.eurosciconnews.com.

I don’t want my photograph on any Euroscicon promotional material
Please let our tech person know.

Is there WIFI?
Yes, please ask registration for log in details.

Can I have a CPD certificate?
Your CPD certificate will be available after lunch in the exhibition area.

Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations.

Euroscicon Ltd UK, Company Number: 4326921, Registered address: 47 High Street, Barnet, Herts, EN5 5UW